We mainly identified that compared to non‐diabetic patients with COVID‐19, patients with DM were older, more likely to have hypertension, a higher blood glucose on admission, be taking ACE inhibitors or ARBs and have a higher platelet count but lower lymphocytes, AST and ALP. This evidence concerns the gene ACE and COVID-19.